Erythritol-based dry powder of glucagon for pulmonary administration

• Published in: International journal of pharmaceutics Vol. 290; no. 1; pp. 63 - 71
• Main Authors: Endo, Kosuke, Amikawa, Satoko, Matsumoto, Asami, Sahashi, Norio, Onoue, Satomi
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 16.02.2005; Elsevier
• Subjects: Administration, Inhalation; Animals; Biological and medical sciences; Blood Glucose - drug effects; Blood Glucose - metabolism; Carrier; Dry powder inhalant; Erythritol; Erythritol - administration & dosage; Erythritol - chemistry; Excipient; General pharmacology; Glucagon; Glucagon - administration & dosage; Glucagon - blood; Lung - drug effects; Lung - metabolism; Male; Medical sciences; Particle Size; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Powders; Pulmonary absorption; Rats; Rats, Sprague-Dawley; Dry powder inhalant; Excipient; Carrier; Glucagon; Pulmonary absorption; Erythritol; Pancreatic hormone; Pharmaceutical technology; Hyperglycemic substances; Lung; Peptide hormone; Vehicle(excipient); Powder; Absorption; Pharmacokinetics; Antidote

Glucagon, a key regulatory element of glycogen metabolism, is known to be effective in the clinical treatment of hypoglycemia and the maintenance of normal circulating glucose levels in patients with total pancreatectomy, however the clinical use of this gut hormone has been restricted to parenteral...